Renjin Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Renjin Chen has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
He Zhang
Comprehensive Laboratory for Biology Teaching, College of Life Sciences, Xuzhou Medical University, Xuzhou, Jiangsu, China
6 shared publicationsXin Li
Comprehensive Laboratory for Biology Teaching, College of Life Sciences, Xuzhou Medical University, Xuzhou, Jiangsu, China
6 shared publicationsYang Chen
Comprehensive Laboratory for Biology Teaching, College of Life Sciences, Xuzhou Medical University, Xuzhou, Jiangsu, China
6 shared publicationsZhenzhen Wang
Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China
6 shared publicationsQuangang Chen
Xuzhou Medical University Xuzhou Jiangsu China
5 shared publicationsShuai Yang
Comprehensive Laboratory for Biology Teaching, College of Life Sciences, Xuzhou Medical University, Xuzhou, Jiangsu, China
5 shared publications
Latest Publications
- 31 January 2026
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 33 (8) , 1634-1647
eIF6 deficiency alleviates colorectal cancer by modulating the gut microbiota and related metabolites
EIF6 is overexpressed in multiple cancers. Previous work has showed that deficiency alters the gut microbiota. This study investigated the mechanism linking eIF6 deficiency, microbial dysbiosis, and colorectal cancer (CRC). eIF6 expression was assessed in human and mouse CRC samples. Functional assays were conducted in mice with AOM/DSS-induced CRC. Antibiotic treatment and faecal microbiota transplantation (FMT) were applied to evaluate microbiota-mediated effects. 16S rDNA sequencing and Dubosiella newyorkensis (D. newyorkensis) supplementation were used to identify key bacteria. Metabolites from the bacterial supernatant were analysed via targeted mass spectrometry. The effect of indole-3-carboxaldehyde (3-ICA) was tested in murine models. eIF6 expression was upregulated in CRC. Its deficiency reduced the tumour incidence and proliferation of tumours in mice and increased the abundance of beneficial bacteria such as Akkermansia and Dubosiella. FMT from eIF6 deficient mice and D. newyorkensis administration attenuated tumorigenesis and enhanced barrier function. 3-ICA, a metabolite of D. newyorkensis, also suppressed CRC progression. eIF6 deficiency exerts protective effects against CRC through the enrichment of D. newyorkensis and its metabolite 3-ICA, revealing a novel mechanism and potential therapeutic strategy for CRC.
- 31 January 2026
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 33 (8) , 1634-1647
eIF6 deficiency alleviates colorectal cancer by modulating the gut microbiota and related metabolites
EIF6 is overexpressed in multiple cancers. Previous work has showed that deficiency alters the gut microbiota. This study investigated the mechanism linking eIF6 deficiency, microbial dysbiosis, and colorectal cancer (CRC). eIF6 expression was assessed in human and mouse CRC samples. Functional assays were conducted in mice with AOM/DSS-induced CRC. Antibiotic treatment and faecal microbiota transplantation (FMT) were applied to evaluate microbiota-mediated effects. 16S rDNA sequencing and Dubosiella newyorkensis (D. newyorkensis) supplementation were used to identify key bacteria. Metabolites from the bacterial supernatant were analysed via targeted mass spectrometry. The effect of indole-3-carboxaldehyde (3-ICA) was tested in murine models. eIF6 expression was upregulated in CRC. Its deficiency reduced the tumour incidence and proliferation of tumours in mice and increased the abundance of beneficial bacteria such as Akkermansia and Dubosiella. FMT from eIF6 deficient mice and D. newyorkensis administration attenuated tumorigenesis and enhanced barrier function. 3-ICA, a metabolite of D. newyorkensis, also suppressed CRC progression. eIF6 deficiency exerts protective effects against CRC through the enrichment of D. newyorkensis and its metabolite 3-ICA, revealing a novel mechanism and potential therapeutic strategy for CRC.
- Open Access
- 21 January 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 16, 1751844
Feeding patterns reprogram a gut microbial virulence–iron–quorum sensing functional axis linked to atherosclerotic risk
The feeding rhythm is a major temporal regulator of metabolic physiology, yet its impact on microbiome-derived functional traits relevant to cardiometabolic disease remains insufficiently understood. Our previous work demonstrated that ad libitum, daytime-restricted, and nighttime-restricted feeding produce markedly different atherosclerotic outcomes in Apoe − / − mice, indicating that the feeding rhythm acts as a modifiable determinant of atherogenic susceptibility. Here, we used shotgun metagenomics to profile risk-associated microbial functional modules—including Type III and Type VI secretion systems (T3SS/T6SS), siderophore-based iron acquisition pathways, quorum-sensing (QS) regulators, and antimicrobial resistance determinants—across feeding regimens. The feeding rhythm induced pronounced functional segregation independent of α -diversity, which was consistent with selective functional reprogramming rather than taxonomic restructuring. Daytime feeding, which is misaligned with the murine active phase, is associated with coordinated enrichment of the T3SS/T6SS, iron uptake, and QS pathways, forming a tightly interconnected “virulence–iron–QS–ARG” functional consortium. In contrast, circadian-aligned nighttime feeding resulted in attenuated virulence orientation and enhanced metabolic-cooperative signatures. Network inference further revealed strong coactivation of virulence secretion, iron mobilization, and QS modules under circadian misalignment. These findings show that the feeding rhythm modulates atherogenic susceptibility not only through host metabolism but also by remodeling gut microbial functional capacities, highlighting microbial functional ecology as an integral component of diet–host interactions.
- 21 January 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 16, 1751844
Open AccessFeeding patterns reprogram a gut microbial virulence–iron–quorum sensing functional axis linked to atherosclerotic risk
The feeding rhythm is a major temporal regulator of metabolic physiology, yet its impact on microbiome-derived functional traits relevant to cardiometabolic disease remains insufficiently understood. Our previous work demonstrated that ad libitum, daytime-restricted, and nighttime-restricted feeding produce markedly different atherosclerotic outcomes in Apoe − / − mice, indicating that the feeding rhythm acts as a modifiable determinant of atherogenic susceptibility. Here, we used shotgun metagenomics to profile risk-associated microbial functional modules—including Type III and Type VI secretion systems (T3SS/T6SS), siderophore-based iron acquisition pathways, quorum-sensing (QS) regulators, and antimicrobial resistance determinants—across feeding regimens. The feeding rhythm induced pronounced functional segregation independent of α -diversity, which was consistent with selective functional reprogramming rather than taxonomic restructuring. Daytime feeding, which is misaligned with the murine active phase, is associated with coordinated enrichment of the T3SS/T6SS, iron uptake, and QS pathways, forming a tightly interconnected “virulence–iron–QS–ARG” functional consortium. In contrast, circadian-aligned nighttime feeding resulted in attenuated virulence orientation and enhanced metabolic-cooperative signatures. Network inference further revealed strong coactivation of virulence secretion, iron mobilization, and QS modules under circadian misalignment. These findings show that the feeding rhythm modulates atherogenic susceptibility not only through host metabolism but also by remodeling gut microbial functional capacities, highlighting microbial functional ecology as an integral component of diet–host interactions.
- Open Access
- 1 January 2026
- Published by BMFH Press in Bioscience of Microbiota, Food and Health
- Vol. 45 (3) , 188-196
Host genotype is associated with selective colonization of human fecal microbiota in NCG and SGM3 mice: implications for microbiota-based therapies
Humanized mouse models are widely used to investigate host–microbiota interactions, yet the extent to which host background contributes to engraftment fidelity remains incompletely defined. In this study, we transplanted fecal microbiota from healthy human donors into NCG and SGM3 mice and characterized engraftment using 16S rRNA sequencing. Both models exhibited reduced diversity relative to donors, but their colonization trajectories diverged. NCG recipients appeared closer to donors in β-diversity space, a pattern largely associated with the expansion of a limited set of opportunistic Proteobacteria such as Escherichia–Shigella and Citrobacter. In contrast, SGM3 mice displayed modestly higher α-diversity and retained a broader set of donor-associated genera, with selective enrichment of Bacillus, yet exhibited greater predicted functional divergence, with reductions in pathways related to ABC transport and carbohydrate metabolism. Several strictly anaerobic commensals, including Faecalibacterium, failed to colonize in either genotype. Collectively, these findings suggest that host genotype is associated with selective colonization of human fecal microbiota and support the utility of integrating compositional and functional criteria when selecting experimental models for translational microbiome research.
- 1 January 2026
- Published by BMFH Press in Bioscience of Microbiota, Food and Health
- Vol. 45 (3) , 188-196
Open AccessHost genotype is associated with selective colonization of human fecal microbiota in NCG and SGM3 mice: implications for microbiota-based therapies
Humanized mouse models are widely used to investigate host–microbiota interactions, yet the extent to which host background contributes to engraftment fidelity remains incompletely defined. In this study, we transplanted fecal microbiota from healthy human donors into NCG and SGM3 mice and characterized engraftment using 16S rRNA sequencing. Both models exhibited reduced diversity relative to donors, but their colonization trajectories diverged. NCG recipients appeared closer to donors in β-diversity space, a pattern largely associated with the expansion of a limited set of opportunistic Proteobacteria such as Escherichia–Shigella and Citrobacter. In contrast, SGM3 mice displayed modestly higher α-diversity and retained a broader set of donor-associated genera, with selective enrichment of Bacillus, yet exhibited greater predicted functional divergence, with reductions in pathways related to ABC transport and carbohydrate metabolism. Several strictly anaerobic commensals, including Faecalibacterium, failed to colonize in either genotype. Collectively, these findings suggest that host genotype is associated with selective colonization of human fecal microbiota and support the utility of integrating compositional and functional criteria when selecting experimental models for translational microbiome research.
- Open Access
- 1 October 2025
- Published by Tsinghua University Press in Food Science and Human Wellness
Dietary Timing Modulates Bile Acid Metabolism and TGR5 Activation to Influence Atherosclerotic Progression
Feeding patterns are emerging as critical regulators of cardiometabolic health; however, their impact on atherosclerotic cardiovascular disease (ASCVD) remains incompletely understood. Here, we demonstrate that feeding during the active phase (i.e., the dark/nighttime phase, when mice are active), either ad libitum (unrestricted access) or restricted to the nighttime (limited to the dark phase), confers significant protection against atherosclerosis in Apoe⁻/⁻ mice, compared to misaligned feeding during the inactive phase (restricted to the light phase). Multi–omics integration revealed that this atheroprotective effect is mediated by gut microbiota–driven modulation of bile acid (BA) metabolism, particularly involving taurolithocholic acid (TLCA), a potent agonist of the G protein–coupled bile acid receptor TGR5. Daytime feeding disrupted the relative abundance of BA–transforming taxa (e.g., Dubosiella, Clostridium) and downregulated key microbial genes (baiA, baiB, cbh, hdhA, and AMACR), leading to reduced TLCA biosynthesis. Despite unaltered hepatic expression of BAAT, FXR, and CYP7A1, compensatory upregulation of CYP7B1 was insufficient to restore TLCA levels. Consequently, impaired vascular TGR5 signaling promoted endothelial inflammation and reduced cholesterol efflux by downregulating ABCA1 expression, thereby facilitating plaque formation. These findings identify the microbiota–BA–TGR5 axis as a critical mediator of feeding rhythm–linked atheroprotection and underscore the therapeutic potential of chrono–nutrition in ASCVD prevention.
- 1 October 2025
- Published by Tsinghua University Press in Food Science and Human Wellness
Open AccessDietary Timing Modulates Bile Acid Metabolism and TGR5 Activation to Influence Atherosclerotic Progression
Feeding patterns are emerging as critical regulators of cardiometabolic health; however, their impact on atherosclerotic cardiovascular disease (ASCVD) remains incompletely understood. Here, we demonstrate that feeding during the active phase (i.e., the dark/nighttime phase, when mice are active), either ad libitum (unrestricted access) or restricted to the nighttime (limited to the dark phase), confers significant protection against atherosclerosis in Apoe⁻/⁻ mice, compared to misaligned feeding during the inactive phase (restricted to the light phase). Multi–omics integration revealed that this atheroprotective effect is mediated by gut microbiota–driven modulation of bile acid (BA) metabolism, particularly involving taurolithocholic acid (TLCA), a potent agonist of the G protein–coupled bile acid receptor TGR5. Daytime feeding disrupted the relative abundance of BA–transforming taxa (e.g., Dubosiella, Clostridium) and downregulated key microbial genes (baiA, baiB, cbh, hdhA, and AMACR), leading to reduced TLCA biosynthesis. Despite unaltered hepatic expression of BAAT, FXR, and CYP7A1, compensatory upregulation of CYP7B1 was insufficient to restore TLCA levels. Consequently, impaired vascular TGR5 signaling promoted endothelial inflammation and reduced cholesterol efflux by downregulating ABCA1 expression, thereby facilitating plaque formation. These findings identify the microbiota–BA–TGR5 axis as a critical mediator of feeding rhythm–linked atheroprotection and underscore the therapeutic potential of chrono–nutrition in ASCVD prevention.
- 17 September 2025
- Published by Wiley in IUBMB Life
- Vol. 77 (9) , e70046
Pan‐Cancer Analysis Identifies DIP2B as a Potential Biomarker That Inhibits Kidney Renal Clear Cell Carcinoma Progression
Disco interacting protein 2 homolog B (DIP2B) is a protein‐coding gene implicated in various biological processes, including embryonic development, cell cycle regulation, DNA repair, and transcriptional regulation. While its precise role in cancer remains largely unknown, emerging evidence suggests its potential involvement in tumorigenesis. In this study, we provide a comprehensive analysis of DIP2B in cancer, exploring its expression patterns, molecular functions, and potential clinical implications across different cancer types. We examined the expression, dysregulation, and prognostic significance of DIP2B. The mRNA and protein expression status of DIP2B was determined using data from TCGA, GTEx, and UALCAN. Using TCGA database data, we investigated associations between DIP2B expression and gene mutations, survival outcomes, DNA methylation, immune cell infiltration, tumor mutation burden (TMB), and drug sensitivity. High DIP2B expression was associated with poor overall survival (OS) in BRCA, KICH, LUAD, MESO, SARC, and THCA, but with improved OS in KIRC. For disease‐specific survival (DSS), elevated DIP2B levels correlated with adverse outcomes in ACC, MESO, and UVM. GO and KEGG analyses implicated DIP2B in cytoskeleton organization, MAPK signaling, and ubiquitin‐dependent protein catabolism. Experimental validation in KIRC cells showed that DIP2B knockdown significantly reduced cell proliferation and migration. Conversely, DIP2B exhibited oncogenic functions in LUAD cells. These findings suggest DIP2B may serve as a potential prognostic and diagnostic biomarker, displaying a unique tumor‐suppressive role in KIRC progression.
- 17 September 2025
- Published by Wiley in IUBMB Life
- Vol. 77 (9) , e70046
Pan‐Cancer Analysis Identifies DIP2B as a Potential Biomarker That Inhibits Kidney Renal Clear Cell Carcinoma Progression
Disco interacting protein 2 homolog B (DIP2B) is a protein‐coding gene implicated in various biological processes, including embryonic development, cell cycle regulation, DNA repair, and transcriptional regulation. While its precise role in cancer remains largely unknown, emerging evidence suggests its potential involvement in tumorigenesis. In this study, we provide a comprehensive analysis of DIP2B in cancer, exploring its expression patterns, molecular functions, and potential clinical implications across different cancer types. We examined the expression, dysregulation, and prognostic significance of DIP2B. The mRNA and protein expression status of DIP2B was determined using data from TCGA, GTEx, and UALCAN. Using TCGA database data, we investigated associations between DIP2B expression and gene mutations, survival outcomes, DNA methylation, immune cell infiltration, tumor mutation burden (TMB), and drug sensitivity. High DIP2B expression was associated with poor overall survival (OS) in BRCA, KICH, LUAD, MESO, SARC, and THCA, but with improved OS in KIRC. For disease‐specific survival (DSS), elevated DIP2B levels correlated with adverse outcomes in ACC, MESO, and UVM. GO and KEGG analyses implicated DIP2B in cytoskeleton organization, MAPK signaling, and ubiquitin‐dependent protein catabolism. Experimental validation in KIRC cells showed that DIP2B knockdown significantly reduced cell proliferation and migration. Conversely, DIP2B exhibited oncogenic functions in LUAD cells. These findings suggest DIP2B may serve as a potential prognostic and diagnostic biomarker, displaying a unique tumor‐suppressive role in KIRC progression.
- 12 June 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 161, 115048
VEGFB167 drives tumor progression by modulating the immune microenvironment
- 12 June 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 161, 115048
VEGFB167 drives tumor progression by modulating the immune microenvironment
- 9 April 2025
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 16 (9) , 3423-3438
Loss of diurnal oscillatory rhythms in gut microbiota correlates with progression of atherosclerosis
Circadian dysregulation of intestinal microbiota in Apoe −/− mice exerts a causal effect on ASCVD pathogenesis. Notably, B.coccoides attenuates ASCVD progression via gallic acid-mediated enhancement of colonic and aortic endothelial barrier functions.
- 9 April 2025
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 16 (9) , 3423-3438
Loss of diurnal oscillatory rhythms in gut microbiota correlates with progression of atherosclerosis
Circadian dysregulation of intestinal microbiota in Apoe −/− mice exerts a causal effect on ASCVD pathogenesis. Notably, B.coccoides attenuates ASCVD progression via gallic acid-mediated enhancement of colonic and aortic endothelial barrier functions.
- Open Access
- 4 January 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (1) , e010521
Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma
Background: Siglec-E is an immune checkpoint inhibitory molecule. Expression of Siglec-E on the immune cells has been shown to promote tumor regression. This study aimed to develop an adenovirus (Ad) vaccine targeting Siglec-E and carbonic anhydrase IX (CAIX) (Ad-Siglec-E/CAIX) and to evaluate its potential antitumor effects in several preclinical renal cancer models. Methods: Ad vaccines encoding Siglec-E or CAIX were developed and evaluated for their therapeutic potential in mouse subcutaneous, lung metastatic, and orthotopic tumor models. The expression of Ad-Siglec-E/CAIX was confirmed via PCR and flow cytometry. Immune responses induced by Ad-Siglec-E/CAIX were assessed in vitro and in vivo using flow cytometry, immunohistochemistry, ELISA, histological analysis, cell proliferation, enzyme-linked immunosorbent spot, cytotoxic T lymphocytes (CTL) killing, and cell depletion assays. Results: Ad-Siglec-E/CAIX vaccine induced the increase of tumor-infiltrated immune cells, and significantly suppressed the subcutaneous tumor growth of renal carcinoma. Immunization with Ad-Siglec-E/CAIX promoted the induction and maturation of CD11c+ dendritic cells and their subsets, which in turn enhanced tumor-specific CD8+ T cell immune responses, as evidenced by increased CD8+ T cell proliferation and CTL activity. Importantly, the deletion of CD8+ T cells in vivo abolished the antitumor effect of the Ad-Siglec-E/CAIX vaccine, highlighting the essential role of functional CD8+ T cell responses. The potent therapeutic efficacy of the Ad-Siglec-E/CAIX vaccine was also observed in lung metastasis and orthotopic tumor models through tumor-specific CD8+ T cell immune responses. Conclusions: Our results indicate that targeting Siglec-E enhances the therapeutic efficacy of Ad-CAIX against renal carcinoma, providing a promising therapeutic option for solid tumors.
- 4 January 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (1) , e010521
Open AccessTargeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma
Background: Siglec-E is an immune checkpoint inhibitory molecule. Expression of Siglec-E on the immune cells has been shown to promote tumor regression. This study aimed to develop an adenovirus (Ad) vaccine targeting Siglec-E and carbonic anhydrase IX (CAIX) (Ad-Siglec-E/CAIX) and to evaluate its potential antitumor effects in several preclinical renal cancer models. Methods: Ad vaccines encoding Siglec-E or CAIX were developed and evaluated for their therapeutic potential in mouse subcutaneous, lung metastatic, and orthotopic tumor models. The expression of Ad-Siglec-E/CAIX was confirmed via PCR and flow cytometry. Immune responses induced by Ad-Siglec-E/CAIX were assessed in vitro and in vivo using flow cytometry, immunohistochemistry, ELISA, histological analysis, cell proliferation, enzyme-linked immunosorbent spot, cytotoxic T lymphocytes (CTL) killing, and cell depletion assays. Results: Ad-Siglec-E/CAIX vaccine induced the increase of tumor-infiltrated immune cells, and significantly suppressed the subcutaneous tumor growth of renal carcinoma. Immunization with Ad-Siglec-E/CAIX promoted the induction and maturation of CD11c+ dendritic cells and their subsets, which in turn enhanced tumor-specific CD8+ T cell immune responses, as evidenced by increased CD8+ T cell proliferation and CTL activity. Importantly, the deletion of CD8+ T cells in vivo abolished the antitumor effect of the Ad-Siglec-E/CAIX vaccine, highlighting the essential role of functional CD8+ T cell responses. The potent therapeutic efficacy of the Ad-Siglec-E/CAIX vaccine was also observed in lung metastasis and orthotopic tumor models through tumor-specific CD8+ T cell immune responses. Conclusions: Our results indicate that targeting Siglec-E enhances the therapeutic efficacy of Ad-CAIX against renal carcinoma, providing a promising therapeutic option for solid tumors.
- Open Access
- 22 October 2024
- Published by American Society for Microbiology in mSystems
- Vol. 9 (10) , e0059524
eIF6 deficiency regulates gut microbiota, decreases systemic inflammation, and alleviates atherosclerosis
Altered composition of the gut microbiota affects immunity and metabolism. This study previously found that eIF6 gene knockdown changes the composition of the intestinal flora in the eIF6 gene knockdown mouse model. Lactobacillus acidophilus is significantly increased in the model. This study was designed to investigate the role of L. acidophilus in the pathogenesis of atherosclerosis. Transcriptomic data from 117 patients with coronary artery disease (CAD) and 79 healthy individuals were obtained. ApoE −/− and ApoE −/− / eIF6 +/− mice on normal chow diet or a high-fat diet were treated for 16 weeks; eIF6 deficiency was evaluated atherosclerosis. ApoE −/− mice on normal chow diet or a high-fat diet were treated with L. acidophilus by daily oral gavage for 16 weeks. Moreover, one group was treated with lipopolysaccharide at 12 weeks. The levels of eIF6 , RNASE3 , and RSAD2 were notably higher in the patients with CAD than in the healthy individuals. eIF6 deficiency altered the composition of gut microbiota. eIF6 deficiency reduced the atherosclerotic lesion formation in ApoE −/− / eIF6 +/− mice compared with the ApoE −/− mice. The microbial sequencing and metabolomics analysis demonstrated some beneficial bacterial ( L. acidophilus , Ileibacterium , and Bifidobacterium ) and metabolic levels significantly had deference in ApoE −/− / eIF6 +/− mice compared with the ApoE −/− mice. Correlational studies indicated that L. acidophilus had close correlations with low-density lipoprotein cholesterol, lesion area, and necrotic area. L. acidophilus inhibited high-fat diet-induced inflammation and atherosclerotic lesion, increasing the expression of tight junction proteins (ZO-1 and claudin-1) and reducing the gut permeability. However, lipopolysaccharide reversed the protective effect of L. acidophilus against atherosclerosis. eIF6 deficiency protected against atherosclerosis by regulating the composition of gut microbiota and metabolites. L. acidophilus attenuated atherosclerotic lesions by reducing inflammation and increasing gut permeability. IMPORTANCE: eIF6 deficiency modulates the gut microbiota and multiple metabolites in atherosclerotic ApoE −/− mice. L. acidophilus was reduced in the gut of atherosclerotic ApoE −/− mice, but administration of Lactobacillus acidophilus reversed intestinal barrier dysfunction and vascular inflammation. Our findings suggest that targeting individual species is a beneficial therapeutic strategy to prevent inflammation and atherosclerosis.
- 22 October 2024
- Published by American Society for Microbiology in mSystems
- Vol. 9 (10) , e0059524
Open AccesseIF6 deficiency regulates gut microbiota, decreases systemic inflammation, and alleviates atherosclerosis
Altered composition of the gut microbiota affects immunity and metabolism. This study previously found that eIF6 gene knockdown changes the composition of the intestinal flora in the eIF6 gene knockdown mouse model. Lactobacillus acidophilus is significantly increased in the model. This study was designed to investigate the role of L. acidophilus in the pathogenesis of atherosclerosis. Transcriptomic data from 117 patients with coronary artery disease (CAD) and 79 healthy individuals were obtained. ApoE −/− and ApoE −/− / eIF6 +/− mice on normal chow diet or a high-fat diet were treated for 16 weeks; eIF6 deficiency was evaluated atherosclerosis. ApoE −/− mice on normal chow diet or a high-fat diet were treated with L. acidophilus by daily oral gavage for 16 weeks. Moreover, one group was treated with lipopolysaccharide at 12 weeks. The levels of eIF6 , RNASE3 , and RSAD2 were notably higher in the patients with CAD than in the healthy individuals. eIF6 deficiency altered the composition of gut microbiota. eIF6 deficiency reduced the atherosclerotic lesion formation in ApoE −/− / eIF6 +/− mice compared with the ApoE −/− mice. The microbial sequencing and metabolomics analysis demonstrated some beneficial bacterial ( L. acidophilus , Ileibacterium , and Bifidobacterium ) and metabolic levels significantly had deference in ApoE −/− / eIF6 +/− mice compared with the ApoE −/− mice. Correlational studies indicated that L. acidophilus had close correlations with low-density lipoprotein cholesterol, lesion area, and necrotic area. L. acidophilus inhibited high-fat diet-induced inflammation and atherosclerotic lesion, increasing the expression of tight junction proteins (ZO-1 and claudin-1) and reducing the gut permeability. However, lipopolysaccharide reversed the protective effect of L. acidophilus against atherosclerosis. eIF6 deficiency protected against atherosclerosis by regulating the composition of gut microbiota and metabolites. L. acidophilus attenuated atherosclerotic lesions by reducing inflammation and increasing gut permeability. IMPORTANCE: eIF6 deficiency modulates the gut microbiota and multiple metabolites in atherosclerotic ApoE −/− mice. L. acidophilus was reduced in the gut of atherosclerotic ApoE −/− mice, but administration of Lactobacillus acidophilus reversed intestinal barrier dysfunction and vascular inflammation. Our findings suggest that targeting individual species is a beneficial therapeutic strategy to prevent inflammation and atherosclerosis.
- Open Access
- 3 October 2024
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (10) , e0043624
A novel clinically relevant human fecal microbial transplantation model in humanized mice
The intact immune system of mice exhibits resistance to colonization by exogenous microorganisms, but the gut microbiota profiles of the humanized mice and the patterns of human fecal microbiota colonization remain unexplored. Humanized NCG (huNCG) mice were constructed by injected CD34 +stem cells. 16S rRNA sequencing and fecal microbiota transplantation (FMT) technologies were used to detect the differences in microbiota and selective colonization ability for exogenous community colonization among three mice cohorts (C57BL/6J, NCG, and huNCG). Flow cytometry analysis showed that all huNCG mice had over 25% hCD45 +in peripheral blood. 16S rRNA gene sequence analysis showed that compared with NCG mice, the gut microbiota of huNCG mice were significantly altered. After FMT, the principal coordinates analysis (PCoA) showed that the gut microbial composition of huNCG mice (huNCG-D9) was similar to that of donors. The relative abundance of Firmicutes and Bacteroidetes were significantly increased in huNCG mice compared to NCG mice. Further comparison of ASV sequences revealed that Bacteroides plebeius , Bacteroides finegoldii , Escherichia fergusonii , Escherichia albertii , Klebsiella pneumoniae, and Klebsiella variicola exhibited higher abundance and stability in huNCG mice after FMT. Furthermore, PICRUSt2 analysis showed that huNCG mice had significantly enhanced metabolism and immunity. This study demonstrated that humanized mice are more conducive to colonization within the human gut microbiota, which provides a good method for studying the association between human diseases and microbiota. IMPORTANCE: The gut microbiota and biomarkers of humanized mice are systematically revealed for the first time. The finding that human fecal microbiota colonize humanized mice more stably provides new insights into the study of interactions between immune responses and gut microbiota.
- 3 October 2024
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (10) , e0043624
Open AccessA novel clinically relevant human fecal microbial transplantation model in humanized mice
The intact immune system of mice exhibits resistance to colonization by exogenous microorganisms, but the gut microbiota profiles of the humanized mice and the patterns of human fecal microbiota colonization remain unexplored. Humanized NCG (huNCG) mice were constructed by injected CD34 +stem cells. 16S rRNA sequencing and fecal microbiota transplantation (FMT) technologies were used to detect the differences in microbiota and selective colonization ability for exogenous community colonization among three mice cohorts (C57BL/6J, NCG, and huNCG). Flow cytometry analysis showed that all huNCG mice had over 25% hCD45 +in peripheral blood. 16S rRNA gene sequence analysis showed that compared with NCG mice, the gut microbiota of huNCG mice were significantly altered. After FMT, the principal coordinates analysis (PCoA) showed that the gut microbial composition of huNCG mice (huNCG-D9) was similar to that of donors. The relative abundance of Firmicutes and Bacteroidetes were significantly increased in huNCG mice compared to NCG mice. Further comparison of ASV sequences revealed that Bacteroides plebeius , Bacteroides finegoldii , Escherichia fergusonii , Escherichia albertii , Klebsiella pneumoniae, and Klebsiella variicola exhibited higher abundance and stability in huNCG mice after FMT. Furthermore, PICRUSt2 analysis showed that huNCG mice had significantly enhanced metabolism and immunity. This study demonstrated that humanized mice are more conducive to colonization within the human gut microbiota, which provides a good method for studying the association between human diseases and microbiota. IMPORTANCE: The gut microbiota and biomarkers of humanized mice are systematically revealed for the first time. The finding that human fecal microbiota colonize humanized mice more stably provides new insights into the study of interactions between immune responses and gut microbiota.